Alnylam Pharmaceuticals (ALNY) FCF Margin (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) posted FCF Margin of 4.17% for Q1 2026, down 60.03% on a QoQ basis from 10.43% in Q4 2025, and up 2593.0% year-over-year from 0.15% in Q1 2025.
Alnylam Pharmaceuticals (ALNY) FCF Margin (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' FCF Margin history runs 18 years deep, the most recent figure standing at 4.17% for Q1 2026.
- Quarterly FCF Margin rose 2593.0% year-over-year to 4.17% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15.01% (up 1876.0% YoY) and the FY2025 annual result came in at 12.53%, up 1443.0% from the prior year.
- FCF Margin was 4.17% for Q1 2026 at Alnylam Pharmaceuticals, down from 10.43% in the prior quarter.
- Across five years, FCF Margin topped out at 45.61% in Q3 2023 and bottomed at 88.65% in Q1 2022.
- A 5-year average of 14.54% and a median of 16.94% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin soared 7873 bps — and 2024, when it slumped 4170 bps.
- Alnylam Pharmaceuticals' FCF Margin stood at 59.06% in 2022, then surged by 105 bps to 3.03% in 2023, then tumbled by 678 bps to 17.49% in 2024, then jumped by 160 bps to 10.43% in 2025, then sank by 60 bps to 4.17% in 2026.
- Business Quant data shows ALNY's FCF Margin at 4.17% in Q1 2026, 10.43% in Q4 2025, and 27.12% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 4.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.17% |
| Dec 31, 2025 | 10.43% |
| Sep 30, 2025 | 27.12% |
| Jun 30, 2025 | 18.28% |
| Mar 31, 2025 | -21.76% |
| Dec 31, 2024 | -17.49% |
| Sep 30, 2024 | 3.91% |
| Jun 30, 2024 | 19.00% |
| Mar 31, 2024 | -16.94% |
| Dec 31, 2023 | 3.03% |
| Sep 30, 2023 | 45.61% |
| Jun 30, 2023 | -23.50% |
| Mar 31, 2023 | -56.49% |
| Dec 31, 2022 | -59.06% |
| Sep 30, 2022 | -33.12% |
| Jun 30, 2022 | -61.77% |
| Mar 31, 2022 | -88.65% |
| Dec 31, 2021 | -42.26% |
| Sep 30, 2021 | -85.33% |
| Jun 30, 2021 | -64.83% |